A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation. We examined in vitro effects of binimetinib on 10 human myeloid/lymphoid leukemia cell lines, and found that three of five cell lines with N-RAS mutation and one of five without N-RAS mutation were responsive to treatment with binimetinib. Binimetinib inhibited cell growth mainly by inducing G 1 arrest and this action mechanism was assisted by gene set enrichment analysis. To identify signaling pathways associated with binimetinib response, we examined the status of MAP kinase/ERK and PI3Kinase/Akt pathways. The basal levels of phosphorylated ERK and Akt varied between the cell lines, and the amounts of phosphorylated ERK and Akt appeared to be reciprocal of each other. Interestingly, most of the binimetinib-resistant cell lines revealed strong Akt phosphorylation compared with binimetinib-sensitive ones. The effect of binimetinib may not be predicted by the presence/absence of N-RAS mutation, but rather by Akt phosphorylation status. Moreover, combination of binimetinib with a PI3K/Akt inhibitor showed additive growth-suppressive effects. These results suggest that binimetinib shows potential anti-leukemic effects and the basal level of phosphorylated Akt might serve as a biomarker predictive of therapeutic effect.
Introduction
Although the treatment strategy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been progressed, complete cure is still a difficult issue to be achieved unless hematopoietic stem cell transplantation (HSCT) is applied [1, 2] . Therefore, a new therapeutic option for the patients not being eligible for HSCT has been expected.
A plenty of oncogenes are reported to be involved in pathogenesis and progression of hematological malignancies. RAS is one of the oncogenes first identified and contributes to cell proliferation and survival. Activated RAS by the point mutation induces pathological activation of RAF/ MEK/ERK signaling in various malignant cells. More than 30% of the patients with pancreas, biliary tract and colon cancers have K-RAS mutation within the cancer tissues [3] . In hematological malignancies, RAS is highlighted as one of the driver mutations in AML and MDS [4, 5] , and in fact, 9.8% and 6.7% of the patients with de novo AML and with MDS with excess blasts bear N-RAS mutation, respectively [6] [7] [8] .
A novel RAS inhibitor, binimetinib (MEK162), is a non-ATP-competitive allosteric MEK1/2 inhibitor [9, 10] . Binimetinib suppresses MEK1/2 signaling by binding to another position except the kinase domain of MEK1/2 and has been previously reported to inhibit the growth of cancer cells derived from various tissues such as lung, pancreas, Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1218 5-019-02667 -1) contains supplementary material, which is available to authorized users.
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colon, neuron and skin [11] [12] [13] [14] [15] . Particularly, the study on primary cultured metastatic melanoma cells suggested that the melanoma cells with N-RAS mutation are more susceptible to binimetinib than those without this mutation [15] . Binimetinib also showed the synergic effect by a combination with other molecular targeting drug, when the therapeutic effect of binimetinib alone was often insufficient for suppressing the tumor cell growth [13, 14] . For example, the combination therapy with a CDK4/6 inhibitor was much effective for colon cancer cells with K-RAS mutation both in vitro and in vivo studies [13] . In hematological malignancies, Kerstjens, et al. reported that binimetinib is the potential drug for the patients with childhood acute lymphoblastic leukemia harboring N-RAS mutation [16] . However, the effect of binimetinib in adult acute leukemia and MDS remains unclear.
In this study, we investigated the effect of binimetinib on the growth of myeloid/lymphoid leukemia cell lines with or without N-RAS mutation and demonstrated that it suppressed cell proliferation by the cell cycle G 1 arrest without apparent involvement in apoptotic pathways. Binimetinib showed an additive effect by the combination treatment with a PI3Ki-nase/Akt inhibitor, buparlisib. Since binimetinib-resistant cell lines had a high level of Akt phosphorylation, the susceptibility of leukemia cells to binimetinib may be inversely associated with the level of Akt phosphorylation.
Materials and methods

Reagents
Binimetinib (MEK162) and buparlisib (BKM120) were purchased from Selleck Chemicals, (Houston, Texas, TX, USA). These were dissolved in dimethylsulfoxide and stored at − 80 °C with being protected from light. We used binimetinib or buparlisib at the concentrations up to 10 µM or to 2 µM, respectively.
Cell lines and culture
An MDS-derived myeloblastic cell line, MDS-L, was positive for N-RAS mutation (G12A) and was maintained in RPMI1640 medium supplemented with 10% fetal bovine serum and 100 U/ml IL-3 [17] [18] [19] . As N-RAS mutation-positive human leukemia cell lines, a myeloid cell line HL-60 (Q61L), an erythroleukemia cell line TF-1 (Q61P), a monocytic cell line THP-1 (G12D) and a T lymphoblastic cell line MOLT4 (G12C) were used in this study. On the other hand, as N-RAS mutation-negative human leukemia cell lines, an-MDS-derived cell line F-36P, a T lymphoblastic cell line Jurkat, a chronic myelogenous leukemia-derived blastic cell line K562, a histiocytic lymphoma cell line U937 and a monocytic cell line MOLM13 were also used The morphological assessment was done with May-Gruenwald-Giemsastained cytospin slides.
Mutation analysis of N-RAS and K-RAS
Total RNA was extracted with RNeasy Mini Kit (Qiagen) and RT-PCR was performed using One step RNA PCR Kit (TAKARA BIO, Otsu, Japan) and following primers: N-RAS (sense: TGA GGT TCT TGC TGG TGT GA; antisense: GAA GTC AGG ACC AGG GTG TC), K-RAS (sense: GGA GAG AGG CCT GCT GAA A; antisense: AGC TAA CAG TCT GCA TGG AG) for cDNA synthesis. PCR was performed using GeneAmp PCR system 9700 (Applied Biosystems, Tokyo, Japan) for 30 cycles, each consisting of 30 s at 94°C, 30 s at 60°C and 180 s at 72°C. The products were separated by electrophoresis on 0.8% agarose gel. PCR products were gel purified using Wizard R SV Gel and PCR Clean-up System (Promega Co, Madison, USA), and ligated into the pCR™II-TOPO R vector (Invitrogen by Life Technologies, Tokyo, Japan) according to the manufacturer's instructions. Independent plasmid clones were purified from several bacterial colonies. Some clones per sample were sequenced using the Big Dye terminator ver 3.1 Cycle Sequencing Kit (Applied Biosystems) and ABI Prism 3130 Genetic Analyzer (Applied Biosystems, Tokyo, Japan). Mutations of codons 12, 13 and 61 in HL-60, THP-1, TF-1 and MOLT4 have been described [19] [20] [21] [22] [23] .
Cell growth assay and MTT assay
Cell growth was assessed by counting the number of living cells after trypan blue staining. Cell suspensions were plated into 96-well plates in the presence of the drug or solvent alone, incubated as above at 37 °C for 1-4 days, and analyzed by the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay [18] .
Apoptosis assay
Apoptosis was examined using an AnnexinV Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA) and all samples were analyzed with FACS Calibur flow cytometer and CellQuest software (Becton-Dickinson, Franklin Lakes, NJ, USA) [24, 25] .
Cell cycle analysis
Cells were fixed with 70% methanol for 30 min and treated with 2 mg/ml ribonuclease A (Nacalai Tesque, Kyoto, Japan) for 30 min at 37 °C, then with 50 µg/mL propidium iodide (PI; Sigma, St Louis, MO, USA) for further 20 min at room temperature. All samples were analyzed with FACS Calibur flow cytometer and CellQuest software.
Immunoblotting analysis
Immunoblotting analysis was performed as previously described [26] . Cell lysates of all ten cell lines were prepared in lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.5% TritonX-100, 0.05% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 2 mM phenylmethylsulfonyl fluoride and 1 mM Na 3 VO 4 . The lysates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting analysis was performed as previously described [27] .
Primary antibodies were obtained from Santa Cruz Biotechnology (bcl2, bcl-XL/Xs; Santa Cruz, CA, USA), Cell Signaling Technology (ERK, phosphor-ERK (Thr202/ Thr204), Akt, phospho-Akt (Ser473), S6, phosphor-S6 (Ser235/236), cleaved-PARP (cPARP); Danvers, MA, USA), and Sigma-Aldrich (α-tubulin; St. Louis, Mo, USA). Horseradish peroxidase-conjugated mouse and rabbit antibodies were from GE Healthcare Life Sciences (Piscataway, NJ).
Gene expression profiling and gene set enrichment analysis
Gene expression profiling of HL-60 cells was analyzed in three independent experiments. Treated cells were harvested after 24-h treatment with 100 nM of binimetinib. Total RNA was extracted with RNeasy Mini Kit (Qiagen, Germantown, MD, USA), converted to cDNA and amplified with GeneChip WT Terminal Labeling and Controls Kit (Affymetrix, Santa Clara, CA, USA). The fragmentation, the labeling and the hybridization of cDNA were treated with GeneChip Hybridization, Wash, and Stain Kit (Affymetrix). Chips were scanned with a GeneChip Scanner 3000 7G System (Affymetrix).
The gene set enrichment analysis (GSEA Broad Institute Cambridge, MA, USA) was performed using the gene expression profiling data and by handling the GSEA software. The detail information of these experiments is described in references [28, 29] . In this study, the whole expression change in the gene sets was defined as statistically significant if both the false discovery rate (FDR) q values and the familywise error rate (FWER) p values were less than 0.25.
Statistical analyses
All results are shown as the mean values with ranges. Comparisons between the groups were done using the Dunnett's and Scheffe's tests. Differences were considered statistically significant if p values were less than 0.05. These analyses were carried out using SPSS for Windows version 14.0. Table 1 ). The sensitivity cut-off concentration of the IC 50 value was defined as 1 µM at the culture for 96 h, and hence, we found that the above 4 cell lines were susceptible to binimetinib, whereas the other cell lines were considered to be resistant to binimetinib (Table 1 ). In MOLT4, Jurkat, U937 and MOLM13, binimetinib treatment did not reach their IC 50 in spite of being treated by the maximal concentration (10 µM) at 96 h. Cell counting by trypan blue staining indicated similar data to the result of MTT assay (data not shown). We compared the sensitivity of binimetinib between the cell lines with N-RAS mutation and those without N-RAS mutation. Three out of 4 sensitive cell lines were N-RAS mutation-positive, suggesting that cell lines with N-RAS mutation have a tendency to be susceptible to binimetinib (Table 1) .
Results
Binimetinib
Next, we examined the presence and the degree of apoptosis of binimetinib-treated cell lines by dual staining of annexinV and PI. Unexpectedly, binimetinib hardly induced apoptosis in most cells with only a limited apoptosis-inducing effect on TF-1 and F-36P (Fig. 1b) . We also checked the morphology of binimetinib-treated HL-60, MDS-L, TF-1, THP-1, K562 and Jurkat cells by May-Gruenwald-Giemsa staining and found that the percentage of apoptotic cells was not significantly increased (data not shown). The amount of cleaved PARP (cPARP), a marker of undergoing apoptosis, was weakly increased with the high concentrations (1 and 10 µM at 72 h) of binimetinib treatment in MDS-L, while the amount of cPARP in the other cell lines did not change (data not shown). The expression of bcl-2 family members (Bcl-2, Bcl-XL, Bcl-Xs) did not change by immunoblotting analysis (data not shown).
Because binimetinib has been previously reported to affect the cell cycle, we performed the cell cycle analysis and MDS-L, to binimetinib for 48 h led to the increase in the cell fraction at G 1 phase in a dose-dependent manner, whereas exposure of the other 8 cell lines to high concentration of binimetinib did not significantly increase the G 1 cell fraction (Fig. 1c) .
The susceptibility to binimetinib is related to the status of Akt phosphorylation
We analyzed the amount of ERK, phosphorylated ERK (p-ERK), Akt and phosphorylated Akt (p-Akt) by immunoblotting analysis to determine whether binimetinib actually suppresses MEK/ERK-or PI3K/Akt-mediated signaling pathways. First, the basal levels of p-ERK and p-Akt were Fig. 1 (continued) found to vary one another dependently on the cell lines, and the amount of phosphorylated proteins appeared to be reciprocal between ERK and Akt (Fig. 2a) . Interestingly, binimetinib-resistant cell lines including THP-1, MOLT4, Jurkat, MOLM13 and U937 except for K562 revealed a strong Akt phosphorylation compared with binimetinib-sensitive cell lines (HL-60, TF-1, MDS-L and F-36P) (Fig. 2a) .
We performed the time-course study of the phosphorylation of ERK and Akt on binimetinib-treated HL-60 cells. Figure 2b indicates that binimetinib treatment immediately downregulated the phosphorylation of ERK but the phosphorylation status appeared to recover slightly after 6 h of the treatment and this recovery was reproducible. In Fig. 1 (continued) contrast, the phosphorylation of Akt was originally faint and almost unchanged by the treatment.
Then, we examined the effect of binimetinib on the phosphorylation of ERK and Akt in the other cell lines. As shown in Fig. 2c , binimetinib suppressed ERK phosphorylation ubiquitously regardless of the degree of susceptibility to binimetinib among the cell lines. On the other hand, binimetinib did not affect Akt phosphorylation (Fig. 2c) . We further evaluated the amount of S6 and phosphorylated S6 which is located at the downstream of MEK/ ERK1/2 and PI3K/Akt pathways. Binimetinib reduced S6 phosphorylation in 3 out of 4 sensitive cell lines (HL-60, MDS-L and TF-1) (Fig. 2d) .
Binimetinib possibly affects the expression of the gene set implicated in the G 1 -S transition
To explore the action mechanisms of binimetinib, the molecular pathways regulated by binimetinib were explored using the gene expression profiling of HL-60 cells treated with or without binimetinib for 24 h. Genes whose expression changed by more than 1.5-fold or < 0.66 following the treatment were defined as the regulated genes. In fact, 1019 genes were upregulated and 951 genes downregulated in binimetinib-treated HL-60 cells. To know the gene groups related to the targets of binimetinib, we performed the gene set enrichment analysis (GSEA) and found that the most significantly affected GSEA set was "CYCLIN E-ASSOCIATED EVENTS DURING G1-S TRANSITION" (FDR q val 0.094; FWER p val 0.078) (Fig. 3a-c) . Taken together, the gene expression profiling suggested that binimetinib suppresses the genetic pathway involved in the cell cycle G 1 -S progression in HL-60 cells.
A PI3K/Akt inhibitor, buparlisib, collaboratively enhances the anti-proliferative effect of binimetinib on leukemia cell lines
To determine whether the degree of Akt phosphorylation is related to the sensitivity to a PI3K/Akt inhibitor, we treated 10 cell lines with a PI3K/Akt inhibitor, buparlisib (BKM120) for 48 h and evaluated the growth suppression by MTT assay. The sensitivity to buparlisib of binimetinib-resistant cell lines with high Akt phosphorylation (THP-1, MOLT4, Jurkat, MOLM13 and U937 as indicated in Fig. 2a ) was higher than the cell lines with low phosphorylation (HL-60, MDS-L, TF-1 and F-36P) (Fig. 4a) . Next, we examined the degree of apoptosis of buparlisib-treated cell lines by dual staining of annexin V and PI, and found that buparlisib strongly induced apoptosis in binimetinib-resistant cell lines with high Akt phosphorylation (Fig. 4b) . We further examined the effect of buparlisib on PI3K/Akt pathway in five cell lines with high Akt phosphorylation at steady state using immunoblotting analysis. Buparlisib suppressed Akt phosphorylation in four out of five cell lines (Fig. 4c) .
Because binimetinib alone was insufficient to induce the growth inhibition of leukemia cells, we cultured each cell line with the combined treatment of binimetinib with buparlisib. We demonstrated that this combined treatment enhanced the growth-suppressive effect in TF-1 and F-36P by MTT assay (Fig. 4d) . This combined treatment additively increased the number of apoptotic cells in dual staining of annexinV and PI (Fig. 4e) . 
Discussion
In this study, we investigated the effect of a novel MEK1/2 inhibitor, binimetinib using 10 myeloid/lymphoid leukemia cell lines including 5 with N-RAS mutation and 5 without N-RAS mutation. Some study groups have previously analyzed the relationship between the presence of RAS mutation and the sensitivity to MEK1/2 inhibitors. Yao, et al. [16] . Taken together, most reports concluded as below described, the cells with RAS mutation have a tendency to be more susceptible to MEK1/2 inhibitor compared with the cells without RAS mutation. Nonetheless, there is still indefinite association between the drug sensitivity and RAS mutation. buparlisib for 6 h and the cell lysates were analyzed by immunoblotting analysis for detection of Akt and p-Akt. The amount of protein bands of p-Akt and Akt was measured by densitometry and its ratio was adjusted as 1.0 in the untreated sample and the changes of the ratio of treated samples relative to untreated sample were indicated. d
The growth inhibition effect of the combined treatment of binimetinib with buparlisib on TF-1 and F-36P for 48 h was examined by MTT assay. e In TF-1 and F-36P, the percentage of apoptotic cells induced by the combined treatment of binimetinib with buparlisib was evaluated by flow cytometry using annexin V/PI staining. The single-positive fraction for annexin V implies early apoptosis, and the doublepositive fraction for annexin V/PI implies late apoptosis Watanabe, et al. conducted the phase 1 study of binimetinib in 21 Japanese patients with advanced solid tumors, and in their pharmacokinetic study the C-max of plasma concentrations was approximately 1 µM due to the oral administration with 45 mg twice daily [31] , compatible to the result of the phase 1 study in USA [32] . Since severe adverse effects were not reported, binimetinib may hardly affect non-malignant cells. Therefore, in the present study we defined the cut-off value of sensitivity/resistance by setting the IC 50 as 1 µM. As a result, 3 (75%) out of 4 sensitive cell lines and 2 (33%) out of 6 resistant cell lines had N-RAS mutation, respectively, and there seemed to be no apparent association between the drug sensitivity and the presence/ absence of RAS mutation (Fig. 1a, Table 1 ).
Yao et al. indicated that there was an exceptional case (H522) in which binimetinib effectively inhibited cell growth but only minimally induced apoptosis and autophagy contributed to the growth suppression in H522 [11] . In our study, even though binimetinib suppressed the proliferation of HL-60 and MDS-L, it hardly induced apoptosis (Fig. 1b) . The amount of LC3, an autophagosome membrane-bound form was not increased in these cells after binimetinib treatment (data not shown).
To determine whether binimetinib actually inhibits the MEK/ERK signaling pathway, we examined the kinetics of ERK phosphorylation. First, the basal levels of p-ERK and p-Akt were found to vary one another, depending on the cell lines, and the amount of phosphorylated proteins appeared to be reciprocal between ERK and Akt (Fig. 2a) . Interestingly, all of the binimetinib-resistant cell lines except for K562 revealed a strong Akt phosphorylation compared with binimetinib-sensitive cell lines (Fig. 2a) . Figure 2b indicates that the suppressive effect of binimetinib on ERK phosphorylation was transient and the level of p-ERK appeared to recover slightly. We hypothesized that the daily addition of binimetinib may enhance growth-suppressive effect and treated HL-60 cells with daily addition of 10, 100 or 1000 nM of binimetinib for 4 days, but it did not exert apparent suppressive effect (data not shown).
Binimetinib treatment inhibited ERK phosphorylation in all the cell lines studied, whereas it did not affect the level of p-Akt (Fig. 2c) . These data suggest that even if binimetinib completely inhibited the MEK/ERK signaling pathway, the cells proliferate via another pathway such as PI3K/Akt pathway in binimetinib-resistant cell lines. There are some reports that described the relationship between the susceptibility to MEK1/2 inhibitors and the status of ERK and Akt phosphorylation [11, 30, 33, 34] , but these reports did not indicate a definite association of the susceptibility to MEK1/2 inhibitors with the status of ERK and Akt phosphorylation. Our data suggest that the effect of binimetinib might not be predicted by the presence/absence of N-RAS mutation but rather by the status of Akt phosphorylation.
Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a tumor suppressor gene implicated in a variety of human cancers and it is a major negative regulator of the PI3K/Akt signaling pathway [35] . It has been previously reported that PTEN function is lost in pediatric and adult T-cell leukemia [36] . To confirm PTEN mutation status in used cell lines, we collected data from the website of "Cancer Cell Line Encyclopedia'. Three (MOLT4, Jurkat and U937) of five binimetinib-resistant cell lines with high Akt phosphorylation had PTEN mutation, whereas four binimetinib-sensitive cell lines showed wild-type PTEN (Table 1) . Since PTEN mutation induces the hyper-activation of PI3K/Akt signaling pathway, it may be useful to detect its mutation status for predicting the sensitivity of binimetinib.
To further investigate the anti-proliferative mechanisms of binimetinib, we analyzed the gene expression profile of HL-60 cells treated with binimetinib by GSEA and identified 5 gene sets in which both FDR q values and FWER p values were less than 0.25. Notably, we focused two gene sets associated with the cell cycle, "CYCLIN E-ASSOCIATED EVENTS DURING G1-S TRANSITION" (FDR q values 0.094; FWER p values 0.078) (Fig. 3a, b) and "SCFSKP2 MEDIATED DEGRADATION OF P27 P21″ (FDR q values 0.053; FWER p values 0.201) (data not shown). Cell cycle transition from G 1 to S phase is regulated by SCF complex composed of Skp-1, Skp-2, Cul-1 and Cks1b which mediates ubiquitination of p27. Skp-2 binds to p27, facilitates its ubiquitination and contributes to the turnover of p27 [37] [38] [39] . It has been previously reported that hyperactivation of genes composed of SCF complex and downregulation of p27 causes therapeutic resistance. Overexpression of Cul-1, one of the SCF complex, facilitates cell proliferation via the degradation of p27 and is associated with poor survival [40] [41] [42] . The overexpression of COMMD1 which assists the activity of SCF complex is related to poor prognosis in B-cell lymphoma [43] . Malek et al. purified the CD138-positive fraction from bone marrow of the patients with bortezomibresistant multiple myeloma and identified high expression of CUL1, COMMD1, SKP2, CKS1B mRNA [44] . They finally demonstrated high expression of these genes contributed to poor overall survival. In our study, binimetinib upregulated the expression of CDKN1B (p27), whereas it downregulated the expression of skp-1, skp-2, cul-1 and cks1b in SCF complex (Fig. 3c) , indicating that the inhibition of SCF complex by binimetinib delayed the degradation of p27 by the ubiquitin-proteasome system and consequently induced G 1 arrest.
In the myeloid/lymphoid leukemia cell lines used in the present study, binimetinib alone showed only limited anti-proliferative effect. Therefore, combination of binimetinib with the other agent should be considered. Lee, et al. reported that the combination of binimetinib with a CDK4/6 inhibitor was more effective than each agent alone in the study of colon cancer cells [13] . The combination of a MEK1/2 inhibitor with a PI3K/Akt inhibitor, buparlisib, synergistically induced apoptosis of NSCLCs and melanoma cells [45] [46] [47] . Also in our study, the combination of binimetinib and buparlisib showed additive anti-proliferative and apoptosis-inducing effects on TF-1 and F-36P (Fig. 4) . It was suggested that the combination of binimetinib and buparlisib exerted additive anti-leukemic effect because these two cell lines revealed only faint phosphorylation of both ERK and Akt (Fig. 2a) and might depend on both signaling by piecemeal.
From the data of the present study, Fig. 5 summarizes the possible treatment strategy based on the growth signaling features of leukemia cells.
In the present study, we investigated the effect of a novel MEK1/2 inhibitor, binimetinib using leukemia cell lines. Binimetinib inhibited cell growth mainly by inducing G 1 arrest and this therapeutic mechanism was assisted by the GSEA data. Since the effect of binimetinib might not be predicted by the presence/absence of N-RAS mutation but rather by the status of Akt phosphorylation, the basal level of Akt phosphorylation might serve as a biomarker to expect the therapeutic effect of binimetinib, and the combined treatment of MEK1/2 inhibitor with a PI3K/Akt inhibitor would be a breakthrough in the treatment strategy of refractory hematological malignancies. Since binimetinib strongly suppressed ERK phosphorylation in all 10 cell lines, the susceptibility to binimetinib may be dependent on the status of another signaling pathway, PI3K-Akt. Even if binimetinib completely inhibits the MEK/ERK signaling pathway, it will not show a sufficient anti-proliferative effect if the PI3K/Akt pathway is active. Therefore, the basal level of Akt phosphorylation might serve as a biomarker to expect the therapeutic effect of binimetinib. a The cell lines with high ERK phosphorylation and low Akt phosphorylation (HL-60 and MDS-L) are highly susceptible to binimetinib. b The cell lines with high Akt phosphorylation (Jurkat and MOLM13) are susceptible to buparlisib but not to binimetinib. c The combined treatment of binimetinib with buparlisib exerts an addictive effect on TF-1 and F-36P which exhibit insufficient sensitivity to a single treatment of each drug
